MPL W515L mutation in pediatric essential thrombocythemia

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages

  Farruggia, Piero ^a   D'Angelo, Paolo ^a   La Rosa, Maria ^b   Scibetta, Nunzia ^a   Santangelo, Giuseppe ^a   Lo Bello, Antonio ^a   Duner, Elena ^c   Randi, Maria Luigia ^c   Putti, Maria Caterina ^d   Santoro, Alessandra ^b  

^a ARNAS Ospedali Civico di Cristina e Benfratelli   (Italy)

^b AO Cervello   (Italy)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Childhood; Essential thrombocythemia; MPL; MPL W515L; Myeloproliferative neoplasm

Indexed keywords

DIAZEPAM; GADOLINIUM;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; CASE REPORT; CEREBELLUM; CHILD; CHILDHOOD DISEASE; CONTRAST ENHANCEMENT; CORPUS CALLOSUM; FOLLOW UP; GENE MUTATION; HUMAN; MALE; MESENCEPHALON; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTHEMIA; TONIC CLONIC SEIZURE; WHITE MATTER;

ADULT; AMINO ACID SUBSTITUTION; CHILD, PRESCHOOL; HUMANS; JANUS KINASE 2; MALE; MUTATION, MISSENSE; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84879214087     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24500     Document Type: Article

References (12)

1. Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000; 110:751.
2. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008; 112:844-847.
3. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003; 17:2318-2357.
4. Wolstencroft EC, Hanlon K, Harries LW, et al. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn 2007; 9:42-46.
5. Butcher CM, Hahn U, To LB, et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008; 22:870-873.
6. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103:4198-4200.
7. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 2009; 27:5195-5201.
8. Iscove NN, Sieber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow: Analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 1974; 83:309-320.
9. Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biological features, treatment, and long-term outcome. Blood 2012; 119:2219-2227.
10. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011; 96:607-611.
11. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008; 112:141-149.
12. Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006; 108:3600-3602.